Siragen Pharmaceuticals is a drug discovery and development biotechnology company, focused on novel approaches to treat Aging and Neurodegenerative Disorders.
Siragen is developing a group of small lead molecules that tackles Alzheimer’s disease by novel strategy different from current unsuccessful approaches. These molecules target a specific pathway of the stress response due to oligomer toxicity causing synaptic dysfunction and secondary cell death.
Unmet Medical Need. Aging population worldwide will boom in next 20 years. Neurodegenerative disorders (Alzheimer’s, Parkinson’s, Amyotrophic Lateral Sclerosis) are present in 1 in 5 patients over 65 years old and represent an annual growth over 8%. Actuarial studies have projected an exponential financial burden for the next generations. Current therapies are ineffective in treating the underlying cause or even in stopping the progression of disease. Alzheimer’s disease is the 6th leading cause of death in United States. Affected patients will increase to 100M by 2050 and is being called the “grey tsunami”.